初次截肢的风险非诺贝特组较安慰剂组降低了36%。
The risk of a first amputation was 36 percent lower among people taking fenofibrate than those taking the placebo.
研究发现踝以上截肢风险在服用非诺贝特组和非服用非诺贝特组之间并无显著差异。
The study found virtually no difference in the risk for amputations above the ankle between those who did and did not take fenofibrate.
加利福尼亚大学戴维斯分校的基因组学研究人员蒂特斯·布朗说：“您寻找的是声誉。”
"The thing you are searching for is reputation," says Titus Brown, a genomics researcher at the University of California, Davis.
应用推荐